

Hui-Yan Wang and Da-Qing Shi\*

Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry,  
Chemical Engineering and Materials Science, Soochow University, Suzhou 215123,


People's Republic of China

\*E-mail: dqshi@suda.edu.cn

Received September 27, 2010

DOI 10.1002/jhet.781

Published online 15 October 2011 in Wiley Online Library (wileyonlinelibrary.com).



A series of 4-aryl-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1*H*-pyrazolo[3,4-*b*]quinolin-5(6*H*)-ones were synthesized by the three-component reaction of aromatic aldehydes, 3-methyl-1-phenyl-1*H*-pyrazol-5-amine, and 5,5-dimethyl-1,3-cyclohexanedione in the presence of sodium 1-dodecanesulfonate in aqueous medium. Compared to the previous methods, this new protocol has the advantages of convenient operation, higher yields, lower cost, and environmentally benign procedure.

*J. Heterocyclic Chem.*, **49**, 212 (2012).

## INTRODUCTION

The need to reduce the amount of toxic waste and by-products arising from chemical processes requires increasing emphasis on the use of less toxic and environmentally compatible materials in the design of new synthetic methods [1]. One of the most promising approaches uses water as the reaction medium [2]. Rideout and Breslow, who showed that hydrophobic effects could strongly enhance the rate of several organic reactions, rediscovered the use of water as a solvent in organic reactions in 1980s [3]. In recent years, there has been increasing recognition that water is an attractive medium for many organic reactions [4]. The aqueous medium with respect to organic solvent is less expensive, less dangerous, and environment friendly. Generally, the low solubility of most reagents in water is not an obstacle to the reactivity, which on the contrary, is reduced with the use of cosolvents.


Multicomponent reactions (MCRs), in which multiple reactions are combined into one synthetic operation, have been used extensively to form carbon-carbon bonds in the synthetic chemistry [5]. Such reactions offer a wide range of possibilities for the efficient construction of highly complex molecules in a single procedural step, thus avoiding the complicated purification operations and allowing savings of both solvents and reagents. In the past decade, there have been tremendous developments in three- and four-component reactions and grant efforts continue to be made to develop new MCRs [6].

Pyrazole derivatives exhibit pharmacological activities such as hypotensive, antibacterial, anti-inflammatory, and antitumor properties. In particular, fused pyrazole are known for various biological activities, *e.g.*, pyrazolo[3,4-*b*]quinolines as potential antiviral [7], antimalarial [8], and lowering of serum cholesterol. A number of methods are available for the synthesis of pyrazolo[3,4-*b*]quinolines [9]; the most efficient and commonly used method involves the reaction of aromatic aldehyde, 1,3-dicarbonyl compound, and aminopyrazole in organic solvent such as EtOH [10]. Each of the above methods has its own merits; however, these methods are also plagued by limitation of poor yields, difficult work-up, and effluent pollution. As part of our current studies on the developments of new routes to heterocyclic system in aqueous media [11], we herein described a clean synthesis of pyrazolo[3,4-*b*]quinoline-5(6*H*)-one derivatives by the three-component reaction of aromatic aldehyde, 5,5-dimethyl-1,3-cyclohexanedione, and 3-methyl-1-phenyl-1*H*-pyrazol-5-amine using water as reaction medium (Scheme 1).

## RESULTS AND DISCUSSION

Choosing an appropriate solvent is of crucial importance for the successful organic synthesis. To search for the optimum reaction solvent, the reaction of 4-hydroxybenzaldehyde (**1a**), 5,5-dimethyl-1,3-cyclohexanedione (**2**), and 3-methyl-1-phenyl-1*H*-pyrazol-5-amine (**3**) was examined using H<sub>2</sub>O, acetone, 95% ethanol, DMF and

Scheme 1.



chloroform as solvent, respectively. The results were summarized in Table 1.

From Table 1, it can be seen that this reaction using water as solvent exhibited the most excellent yield. Therefore, water was chosen as the solvent for this reaction. To examine the efficiency and the applicability of this three-component reaction, a series of different aromatic aldehydes were tested in aqueous media. As shown in Table 2, this protocol could be applied to the aromatic aldehydes with either electron-withdrawing groups (such as halide groups) or electron-donating groups (such as alkyl and alkoxy groups). The products were different from those literature reported [10].

Apart from the mild conditions of the process and its excellent results, the simplicity of product isolation and the possibility to recycle the reaction solution offer a significant advantage. Because SDS is soluble in water and the desired product is less soluble in water, the products can be directly separated by cooling to room temperature and filtering after the reaction is completed. The remaining reaction solution can be recycled. Studies using **1a**, **2**, and **3** as model substrates showed that the recovered reaction solution could be successively recycled in subsequent reaction without any decrease of yield (Table 3).

The structures of the products were established on the spectroscopic data. The structure of compound **4k** was further confirmed by X-ray diffraction analysis. The molecular structure of the product **4k** is shown in Figure 1. The crystallographic data of compound **4k** is summarized in Table 4.

Although the detailed mechanism of this reaction has not been clarified yet, the formation of **4** can be explained by the possible mechanism presented in Scheme 2. The

reaction occurs *via* an initial formation of the  $\alpha,\beta$ -unsaturated ketone, from the condensation of aldehyde and 5,5-dimethyl-1,3-cyclohexanedione as shown in Scheme 2, which suffers nucleophilic attack to give the Michael adduct [A]. The intermediate [A] then isomerizes, cyclizes, dehydrates, and subsequently loses a hydrogen molecule to afford the fully aromatized compound. This type of hydrogen loss is well documented [12].

In summary, we developed an efficient three-component reaction of aromatic aldehydes, 5,5-dimethyl-1,3-cyclohexanedione, and 3-methyl-1-phenyl-1H-pyrazol-5-amine for the synthesis of pyrazolo[3,4-*b*]quinolin-5-one derivatives using water as reaction medium. Compared to the previous methods, this new protocol has the advantages of convenient operation, higher yields, low cost, and environmentally benign procedure.

## EXPERIMENTAL

Melting points are uncorrected. IR Spectra were recorded on a FT-IR Tensar 27 spectrometer in KBr with absorptions in  $\text{cm}^{-1}$ .  $^1\text{H-NMR}$  spectra were determined on a Bruker DPX-400 MHz spectrometer using  $\text{DMSO-}d_6$  solutions. Chemical shifts are expressed in ppm downfield from internal tetramethylsilane. High resolution mass spectra were obtained using TOF-MS instrument.

**General procedure for the synthesis of 4-aryl-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo [3,4-*b*]quinolin-5(6*H*)-ones 4.** A mixture of aromatic aldehyde **1** (2 mmol), 5,5-dimethyl-1,3-cyclohexanedione **2** (2 mmol), 3-methyl-1-phenyl-1H-pyrazol-5-amine **3** (2 mmol), and SDS (0.2 g) in

**Table 1**  
Solvent optimization for the synthesis of **4a**.

| Entry | Solvent                           | Reaction temperature (°C) | Time (h) | Isolated yield (%) |
|-------|-----------------------------------|---------------------------|----------|--------------------|
| 1     | H <sub>2</sub> O/SDS              | 90                        | 11       | 98                 |
| 2     | CH <sub>3</sub> COCH <sub>3</sub> | Reflux                    | 11       | 0                  |
| 3     | EtOH                              | Reflux                    | 11       | 35                 |
| 4     | DMF                               | 90                        | 11       | 18                 |
| 5     | CHCl <sub>3</sub>                 | Reflux                    | 11       | 12                 |

**Table 2**  
The synthesis of **4** in aqueous medium.

| Entry | Product   | Ar   | Time (h) | Isolated yield (%) |
|-------|-----------|--|----------|--------------------|
| 1     | <b>4a</b> | 4-HOC <sub>6</sub> H <sub>4</sub>                                | 10       | 96                 |
| 2     | <b>4b</b> | 2-ClC <sub>6</sub> H <sub>4</sub>                                | 16       | 86                 |
| 3     | <b>4c</b> | 4-FC <sub>6</sub> H <sub>4</sub>                                 | 10       | 93                 |
| 4     | <b>4d</b> | 3-ClC <sub>6</sub> H <sub>4</sub>                                | 12       | 95                 |
| 5     | <b>4e</b> | 4-ClC <sub>6</sub> H <sub>4</sub>                                | 9        | 95                 |
| 6     | <b>4f</b> | 4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                  | 15       | 97                 |
| 7     | <b>4g</b> | 4-BrC <sub>6</sub> H <sub>4</sub>                                | 12       | 98                 |
| 8     | <b>4h</b> | 4-(CH <sub>3</sub> ) <sub>2</sub> NC <sub>6</sub> H <sub>4</sub> | 17       | 98                 |
| 9     | <b>4i</b> | 3,4-Cl <sub>2</sub> C <sub>6</sub> H <sub>3</sub>                | 6        | 84                 |
| 10    | <b>4j</b> | 3,4-OCH <sub>2</sub> OC <sub>6</sub> H <sub>3</sub>              | 11       | 98                 |
| 11    | <b>4k</b> | 4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>                 | 12       | 97                 |

Table 3

Studies on the reuse of reaction solution in the preparation of 4a.

| Round     | 1  | 2  | 3  | 4  | 5  |
|-----------|----|----|----|----|----|
| Yield (%) | 96 | 95 | 94 | 92 | 92 |

H<sub>2</sub>O (10 mL) was stirred for 6–17 h at 90°C, then cooled to room temperature. The crystalline powder formed was collected by filtration, washed with water. The crude products were purified by recrystallization from DMF to give 4.

**4-(4-Hydroxyphenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one (4a).** M.p.: 281–283°C (ref. 13; M.p.: 277–279°C); IR (potassium bromide): 3304, 3058, 1666, 1613, 1593, 1512, 1456, 1437, 1385, 1264, 1172, 1026, 849, 758 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ: 1.07 (6H, s, 2 × CH<sub>3</sub>), 1.88 (3H, s, CH<sub>3</sub>), 2.51 (2H, s, CH<sub>2</sub>), 3.19 (2H, s, CH<sub>2</sub>), 6.84 (2H, d, *J* = 8.4 Hz, ArH), 7.07 (2H, d, *J* = 8.4 Hz, ArH), 7.35 (1H, t, *J* = 8.0 Hz, ArH), 7.57 (2H, t, *J* = 8.0 Hz, ArH), 8.24 (2H, d, *J* = 8.0 Hz, ArH), 9.60 (1H, s, OH).

**4-(2-Chlorophenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one (4b).** M.p.: 156–158°C; IR (potassium bromide): 3056, 1682, 1593, 1569, 1498, 1479, 1384, 1268, 1125, 853, 753 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ: 1.06 (3H, s, CH<sub>3</sub>), 1.11 (3H, s, CH<sub>3</sub>), 1.81 (3H, s, CH<sub>3</sub>), 2.58 (2H, s, CH<sub>2</sub>), 3.29 (2H, s, CH<sub>2</sub>), 7.34–7.40 (2H, m, ArH), 7.44–7.53 (2H, m, ArH), 7.57–7.61 (3H, m, ArH), 8.25 (2H, d, *J* = 7.6 Hz, ArH); HRMS [Found: *m/z*: 415.1457 (M<sup>+</sup>); Calcd for C<sub>25</sub>H<sub>22</sub>ClN<sub>3</sub>O: M 415.1451].

**4-(4-Fluorophenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one (4c).** M.p.: 170–172°C (ref. 13; M.p.: 172–174°C); IR (potassium bromide): 3062, 1678, 1596, 1561, 1509, 1470, 1455, 1382, 1260, 1158, 1093, 848, 753 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ: 1.08 (6H, s, 2 × CH<sub>3</sub>), 1.84 (3H, s, CH<sub>3</sub>), 2.51 (2H, s, CH<sub>2</sub>), 3.22 (2H, s, CH<sub>2</sub>), 7.28–7.39 (5H, m, ArH), 7.59 (2H, t, *J* = 8.0 Hz, ArH), 8.24 (2H, d, *J* = 8.0 Hz, ArH).




Figure 1. The X-ray crystal structure of compound 4k.

Table 4

Crystallographic data of compound 4k.

|   |  |
|---|--|
| Empirical formula                                   | C <sub>26</sub> H <sub>25</sub> N <sub>3</sub> O <sub>2</sub>  |
| Formula weight                                      | 411.49   |
| Temperature   | 293(2) K   |
| Wavelength  | 0.71073 Å  |
| Crystal system                                      | Monoclinic   |
| Space group   | Pn   |
| Unit cell dimensions                                | <i>a</i> = 14.101(9) Å <i>α</i> = 90°<br><i>b</i> = 7.584(5) Å <i>β</i> = 122.73(3)°<br><i>c</i> = 23.376(11) Å <i>γ</i> = 90° |
| Volume  | 2103(2) Å <sup>3</sup>   |
| <i>Z</i>  | 4  |
| Density (calculated)                                | 1.300 Mg/m <sup>3</sup>  |
| Absorption coefficient                              | 0.083 mm <sup>-1</sup>   |
| <i>F</i> (000)                                      | 872  |
| Crystal size  | 0.29 × 0.18 × 0.11 mm <sup>3</sup>   |
| Theta range for data collection                     | 1.84° to 25.01°  |
| Limiting indices                                    | -16 ≤ <i>h</i> ≤ 16, -8 ≤ <i>k</i> ≤ 9,<br>-19 ≤ <i>l</i> ≤ 27   |
| Reflections collected                               | 10637  |
| Independent reflections                             | 3687 [ <i>R</i> (int) = 0.0712]  |
| Data/restraints/parameters                          | 3687/0/281   |
| Goodness-of-fit on <i>F</i> <sup>2</sup>            | 1.004  |
| Final <i>R</i> indices [ <i>I</i> > 2σ( <i>I</i> )] | <i>R</i> <sub>1</sub> = 0.0524, <i>wR</i> <sub>2</sub> = 0.1056  |
| <i>R</i> indices (all data)                         | <i>R</i> <sub>1</sub> = 0.1316, <i>wR</i> <sub>2</sub> = 0.1365  |
| Largest diff. peak and hole                         | 0.192 and -0.210 e <sup>-</sup> Å <sup>-3</sup>  |


**4-(3-Chlorophenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one (4d).** M.p.: 163–165°C; IR (potassium bromide): 3063, 1685, 1599, 1509, 1483, 1382, 1265, 1128, 985, 758, 736 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ: 1.09 (6H, s, 2 × CH<sub>3</sub>), 1.83 (3H, s, CH<sub>3</sub>), 2.53 (2H, s, CH<sub>2</sub>), 3.22 (2H, s, CH<sub>2</sub>), 7.27 (1H, d, *J* = 7.2 Hz, ArH), 7.37 (1H, t, *J* = 7.2 Hz, ArH), 7.43 (1H, s, ArH), 7.48–7.65 (4H, m, ArH), 8.24 (2H, d, *J* = 8.0 Hz, ArH); HRMS [Found: *m/z*: 415.1445 (M<sup>+</sup>); Calcd for C<sub>25</sub>H<sub>22</sub>ClN<sub>3</sub>O: M 415.1451].

**4-(4-Chlorophenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one (4e).** M.p.: 181–183°C (ref. 13; M.p.: 180–183°C); IR (potassium bromide): 3060, 1680, 1595, 1489, 1455, 1386, 1264, 1126, 844, 752 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ: 1.08 (6H, s, 2 × CH<sub>3</sub>), 1.84 (3H, s, CH<sub>3</sub>), 2.51 (2H, s, CH<sub>2</sub>), 3.21 (2H, s, CH<sub>2</sub>), 7.32–7.38 (3H, m, ArH), 7.53 (2H, d, *J* = 8.4 Hz, ArH), 7.58 (2H, t, *J* = 8.0 Hz, ArH), 8.24 (2H, d, *J* = 8.0 Hz, ArH).

**4-(4-Methylphenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one (4f).** M.p.: 182–184°C (ref. 13; M.p.: 184–186°C); IR (potassium bromide): 3021, 1677, 1591, 1560, 1499, 1455, 1386, 1263, 1126, 803, 752 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ: 1.08 (6H, s, 2 × CH<sub>3</sub>), 1.81 (3H, s, CH<sub>3</sub>), 2.42 (3H, s, CH<sub>3</sub>), 2.51 (2H, s, CH<sub>2</sub>), 3.21 (2H, s, CH<sub>2</sub>), 7.16 (2H, d, *J* = 8.0 Hz, ArH), 7.27 (2H, d, *J* = 8.0 Hz, ArH), 7.36 (1H, t, *J* = 8.0 Hz, ArH), 7.58 (2H, t, *J* = 8.0 Hz, ArH), 8.24 (2H, d, *J* = 8.0 Hz, ArH).

**4-(4-Bromophenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one (4g).** M.p.: 184–186°C (ref. 13; M.p.: 188–189°C); IR (potassium bromide): 3069, 1679, 1592, 1569, 1558, 1498, 1455, 1416, 1386, 1264, 1174, 1099, 909, 843, 752 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ: 1.06 (6H, s, 2 × CH<sub>3</sub>), 1.88 (3H, s, CH<sub>3</sub>), 2.51 (2H, s, CH<sub>2</sub>), 3.21 (2H, s, CH<sub>2</sub>),

Scheme 2. The possible mechanism for the synthesis of compound 4.



7.27 (2H, d,  $J = 8.4$  Hz, ArH), 7.37 (1H, t,  $J = 7.6$  Hz, ArH), 7.58 (2H, t,  $J = 7.6$  Hz, ArH), 7.67 (2H, t,  $J = 8.4$  Hz, ArH), 8.24 (2H, d,  $J = 8.0$  Hz, ArH).

**4-(4-Dimethylaminophenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1*H*-pyrazolo[3,4-*b*]quinolin-5(6*H*)-one (4h).** M.p.: 195–197°C (ref. 13; M.p.: 194–196°C); IR (potassium bromide): 3066, 1687, 1612, 1567, 1506, 1473, 1419, 1385, 1283, 1260, 1201, 1130, 983, 816, 790, 766  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$ : 1.07 (6H, s,  $2 \times \text{CH}_3$ ), 1.92 (3H, s,  $\text{CH}_3$ ), 2.51 (2H, s,  $\text{CH}_2$ ), 2.99 (6H, s,  $(\text{CH}_3)_2\text{N}$ ), 3.19 (2H, s,  $\text{CH}_2$ ), 6.78 (2H, d,  $J = 8.4$  Hz, ArH), 7.09 (2H, d,  $J = 8.8$  Hz, ArH), 7.35 (1H, t,  $J = 7.6$  Hz, ArH), 7.57 (2H, t,  $J = 8.0$  Hz, ArH), 8.25 (2H, d,  $J = 7.6$  Hz, ArH).

**4-(3,4-Dichlorophenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1*H*-pyrazolo[3,4-*b*]quinolin-5(6*H*)-one (4i).** M.p.: 176–178°C (ref. 13; M.p.: 179–181°C); IR (potassium bromide): 3062, 1683, 1598, 1568, 1509, 1482, 1439, 1419, 1385, 1309, 1291, 1264, 1130, 985, 812, 755  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$ : 1.17 (6H, s,  $2 \times \text{CH}_3$ ), 2.00 (3H, s,  $\text{CH}_3$ ), 2.60 (2H, s,  $\text{CH}_2$ ), 3.26 (2H, s,  $\text{CH}_2$ ), 7.14 (1H, dd,  $J_1 = 2.0$  Hz,  $J_2 = 8.0$  Hz, ArH), 7.34 (1H, d,  $J = 7.2$  Hz, ArH), 7.38 (1H, d,  $J = 2.0$  Hz, ArH), 7.53–7.59 (3H, m, ArH), 8.28 (2H, d,  $J = 7.6$  Hz, ArH).

**4-(3,4-Methylenedioxyphenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1*H*-pyrazolo[3,4-*b*]quinolin-5(6*H*)-one (4j).** M.p.: 178–180°C (ref. 13; M.p.: 175–177°C); IR (potassium bromide): 3055, 1672, 1598, 1557, 1507, 1491, 1473, 1456, 1381, 1351, 1291, 1255, 1176, 1037, 934, 810, 752  $\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$ : 1.08 (6H, s,  $2 \times \text{CH}_3$ ), 1.93 (3H, s,  $\text{CH}_3$ ), 2.51 (2H, s,  $\text{CH}_2$ ), 3.20 (2H, s,  $\text{CH}_2$ ), 6.12 (2H, s,  $\text{OCH}_2\text{O}$ ), 6.72 (1H, d,  $J = 7.6$  Hz, ArH), 6.89 (1H, s, ArH), 7.00 (1H, d,  $J = 7.6$  Hz, ArH), 7.36 (1H, t,  $J = 7.6$  Hz, ArH), 7.58 (2H, t,  $J = 7.6$  Hz, ArH), 8.24 (2H, d,  $J = 8.0$  Hz, ArH).

**4-(4-Methoxyphenyl)-3,7,7-trimethyl-1-phenyl-7,8-dihydro-1*H*-pyrazolo[3,4-*b*]quinolin-5(6*H*)-one (4k).** M.p.: 139–141°C (ref. 13; M.p.: 138–140°C); IR (potassium bromide): 3017, 2956, 2868, 2834, 1676, 1608, 1581, 1556, 1514, 1467, 1439, 1410, 0382, 1305, 1292, 1244, 1175, 906, 842, 808, 751, 687

$\text{cm}^{-1}$ ;  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$ : 1.07 (6H, s,  $2 \times \text{CH}_3$ ), 1.85 (3H, s,  $\text{CH}_3$ ), 2.51 (2H, s,  $\text{CH}_2$ ), 3.20 (2H, s,  $\text{CH}_2$ ), 3.84 (s, 3H,  $\text{CH}_3\text{O}$ ), 7.02 (2H, d,  $J = 8.4$  Hz, ArH), 7.20 (2H, d,  $J = 8.4$  Hz, ArH), 7.36 (1H, t,  $J = 7.6$  Hz, ArH), 7.58 (2H, t,  $J = 8.0$  Hz, ArH), 8.24 (2H, d,  $J = 8.0$  Hz, ArH).

**Acknowledgments.** Financial support from the Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions (No. 10KJA150049) and the Foundation of Key Laboratory of Organic Synthesis of Jiangsu Province (No. JSK0812).

## REFERENCES AND NOTES

- [1] (a) Amato, J. *Science* 1993, 259, 1538; (b) Illman, D. L. *Chem Eng News* 1994, 72, 22.
- [2] (a) Li, C. J.; Chang, T. H. *Organic Reactions in Aqueous Media*; Wiley: New York, 1997; (b) Fringuelli, F.; Piermatti, O.; Pizzo, F.; Vaccaro, L. *Eur J Org Chem* 2001, 439.
- [3] (a) Rideout, D. C.; Breslow, R. *J Am Chem Soc* 1980, 102, 7816; (b) Breslow, R. *Acc Chem Res* 1991, 24, 159.
- [4] (a) Li, C. J. *Chem Rev* 1993, 93, 2023; (b) Ballini, R.; Bosica, G. *Tetrahedron Lett* 1996, 37, 8027; (c) Meijer, A.; Otto, S.; Engberts, J. B. F. *N. J Org Chem* 1998, 63, 8989; (d) Bigi, F.; Chesini, L.; Maggi, R.; Sartori, G. *J Org Chem* 1999, 64, 1033; (e) Bigi, F.; Carloni, S.; Ferrari, L.; Maggi, R.; Mazzacani, A.; Sartori, G. *Tetrahedron Lett* 2001, 42, 5203.
- [5] (a) Zhu, J.; Bienayme, H. *Multicomponent Reactions*; Wiley-VCH: Weinheim, 2005; (b) Ramón, D. J.; Yus, M. *Angew Chem Int Ed* 2005, 44, 1602; (c) Simon, C.; Constantieux, T.; Rodriguez, J. *Eur J Org Chem* 2004, 4957; (d) Zhu, J. *Eur J Org Chem* 2003, 1133; (e) Orru, R. V. A.; de Greef, M. *Synthesis* 2003, 1471; (f) Nair, V.; Rajesh, C.; Vinod, A. U.; Bindu, S.; Sreekanth, A. R.; Mathen, J. S.; Balagopal, L. *Acc Chem Res* 2003, 36, 899; (g) Bienaymé, H.; Hulme, C.; Odon, G.; Schmitt, P. *Chem Eur J* 2000, 6, 3321; (h) Dömling, A.; Ugi, I. *Angew Chem Int Ed* 2000, 39, 3168; (i) Tietze, L. F.; Modi, A. *Med Res Rev* 2000, 20, 304.
- [6] (a) Nair, V.; Vinod, A. U.; Rajesh, C. *J Org Chem* 2001, 66, 4427; (b) List, B.; Castello, C. *Synlett* 2001, 1687; (c)

Shestopalov, A. M.; Emeliyanova, Y. M.; Shestopalov, A. A.; Rodinovskaya, L. A.; Niazimbetova, Z. I.; Evans, D. H. *Org Lett* 2002, 4, 423; (d) Bertozzi, F.; Gustafsson, M.; Olsson, R. *Org Lett* 2002, 4, 3147; (e) Bagley, M. C.; Dale, J. W.; Bower, J. *Chem Commun* 2002, 1682; (f) Cheng, J. F.; Chen, M.; Arrhenius, T.; Nadzan, A. *Tetrahedron Lett* 2002, 43, 6293; (g) Huma, H. Z. S.; Halder, R.; Kalra, S. S.; Das, J.; Iqbal, J. *Tetrahedron Lett* 2002, 43, 6485; (h) Bora, U.; Saikia, A.; Boruah, R. C. *Org Lett* 2003, 5, 435.

[7] Sminoff, P.; Crenshaw, R. R. *Antimicrob Agents Chemother* 1977, 11, 571.

[8] Stein, R. G.; Beil, J. H.; Singh, T. *J Med Chem* 1970, 13, 153.

[9] (a) Hayes, R.; Meth-Cohn, O. *Tetrahedron Lett* 1982, 23, 1613; (b) Rajendran, S. P.; Manonmani, M.; Vijayalakshmi, S. *Org Pre Proc Int* 1994, 26, 383; (c) Paul, S.; Gupta, M.; Gupta, R.; Loupy, A. *Tetrahedron Lett* 2001, 42, 3827; (d) Tomasik, D.; Tomasik, P.; Abramovitch, R. A. *J Heterocycl Chem* 1983, 20, 1539.

[10] (a) Quiroga, J.; Insuasty, B.; Hormaza, A.; Saitz, C.; Julian, C. *J Heterocycl Chem* 1998, 35, 575; (b) Quiroga, J.; Alvarado, M.;

Insuasty, B.; Noguerras, M.; Sánchez, A.; López, M. D. *J Heterocycl Chem* 1999, 36, 113; (c) Quiroga, J.; Cruz, S.; Insuasty, B.; Abonia, R.; Cobo, J.; Sánchez, A.; Noguerras, M.; Low, J. N. *J Heterocycl Chem* 2001, 38, 53; (d) Hua, G. P.; Xu, J. N.; Tu, S. J.; Wang, Q.; Zhang, J. P.; Zhu, X. T.; Li, T. J.; Zhu, S. L.; Zhang, X. *J Chin J Org Chem* 2005, 25, 1610.

[11] (a) Shi, D. Q.; Yao, H.; Shi, J. W. *Synth Commun* 2008, 38, 1662; (b) Shi, D. Q.; Shi, J. W.; Yao, H. *Synth Commun* 2009, 39, 664; (c) Shi, D. Q.; Yao, H. *Synth Commun* 2009, 39, 2481; (d) Shi, D. Q.; Niu, L. H.; Shi, J. W.; Wang, X. S.; Ji, S. J. *J Heterocycl Chem* 2007, 44, 1083; (e) Shi, D. Q.; Niu, L. H.; Yao, H.; Jiang, H. *J Heterocycl Chem* 2009, 46, 237; (f) Shi, D. Q.; Shi, J. W.; Rong, S. F. *J Heterocycl Chem* 2009, 46, 1331; (g) Shi, D. Q.; Yao, H. *J Heterocycl Chem* 2009, 46, 1335; (h) Li, Y. L.; Chen, H.; Shi, C. L.; Shi, D. Q.; Ji, S. J. *J Comb Chem* 2010, 12, 231; (i) Chen, H.; Shi, D. Q. *J Comb Chem* 2010, 12, 571.

[12] Dimmock, J. R.; Raghavan, S. K.; Bigam, G. E. *Eur J Med Chem* 1988, 23, 111.

[13] Shi, D. Q.; Yang, F. *J Heterocycl Chem*, to appear.